Skip to main content
Actelion purchased by J&J, spins out Idorsia

Johnson & Johnson's Janssen Pharmaceutical completed its Actelion acquisition for $30 billion in cash. Actelion spun off Idorsia after the acquisition, which has ongoing trials of aprocitentan, or ACT-541468, for chronic insomnia, clazosentan for vasospasm related to aneurysmal subarachnoid hemorrhage and cenerimod for lupus.

Full Story: